arrow
T

Takuya Miyazaki

yokohama city university
H指数:27
被引数:2,704

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial

慢性粒细胞白血病慢性期老年患者低剂量达沙替尼的长期疗效:DAVLEC II期试验的扩展随访研究

2026-05-280
OA
Personalized multivariable clinical prognostic model for patients with acute myeloid leukemia receiving intensive chemotherapy

急性髓系白血病接受强化化疗患者个性化多变量临床预后模型

2026-01-010
PRE
Novel Scoring System Using Geriatric Nutritional Risk Index, C-Reactive Protein, and Disease Status Predicts Survival After Second Allogeneic Stem Cell Transplantation

新型评分系统:基于老年营养风险指数、C-反应蛋白和疾病状态,预测第二次异基因造血干细胞移植后的生存情况

2025-12-040
PRE
Prognostic Value of C-Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma

C-反应蛋白/血小板比率作为生物标志物在恶性淋巴瘤异基因造血干细胞移植前的预后价值

2025-09-080
PRE
Clinical significance of C-reactive protein/platelet ratio from diagnosis to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

急性髓系白血病中C-反应蛋白/血小板比率从诊断到异基因造血干细胞移植的临床意义

2025-07-030
OAAI
Optimal Depth of the Treatment Response Before Allogeneic Hematopoietic Transplantation for Chronic Myeloid Leukemia in Chronic Phase

异基因造血干细胞移植前慢性粒细胞白血病慢性期的最佳治疗反应深度

2025-05-120
PRE
Factors Predicting Spontaneous Regression in Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Diseases

预测其他医源性免疫缺陷相关淋巴增殖性疾病的自发性消退的因素

2025-02-250
PRE
Investigation of biomarkers to predict outcomes in allogeneic hematopoietic stem cell transplantation

预测异基因造血干细胞移植结局的生物标志物研究

2024-08-010
PRE
Pretransplantation Inflammatory and Nutritional Status in Elderly Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Value of C-Reactive Protein-to-Albumin Ratio
2024-04-011
OAAI
The efficacy of high-dose versus intrathecal methotrexate for DLBCL with high risk of CNS relapse: A multicenter retrospective study
2023-11-010
OA
Prognostic significance of the CFA ratio for newly diagnosed acute myeloid leukemia: A multicenter retrospective study
2023-09-201
PRE